Phase II dose-ranging study of veltuzumab in systemic lupus erythematosus.

Trial Profile

Phase II dose-ranging study of veltuzumab in systemic lupus erythematosus.

Planning
Phase of Trial: Phase II

Latest Information Update: 15 May 2013

At a glance

  • Drugs Veltuzumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 15 May 2013 Study title is not official title.
    • 15 May 2013 New trial record
    • 08 May 2013 A pre-IND meeting request and an application for scientific advice have been filed in the USA and European Union, respectively, according to an Immunomedics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top